Please provide your email address to receive an email when new articles are posted on . The study, which was presented at the virtual PCR e-Course and simultaneously published in Circulation, also ...
A small study testing the pharmacodynamic effects of several antiplatelet agents suggests that tirofiban (Aggrastat; Medicure), a glycoprotein IIb/IIIa inhibitor, may provide “more potent and ...
AGGREGATION of platelets in the presence of adenosine diphosphate (ADP) appears to be important in hæmostasis and in the genesis of platelet thrombosis. There is evidence that this reaction is common ...
Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container. Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container.
SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. announced positive data from the company’s completed phase 1 clinical study of RUC-4 which was published in the Journal of the American Heart ...
Please provide your email address to receive an email when new articles are posted on . Patients with STEMI undergoing primary PCI achieved better platelet inhibition by chewing a loading dose of ...
SAN DIEGO--(BUSINESS WIRE)--CeleCor Therapeutics, Inc. today announced preliminary positive results in the company’s ongoing phase 1 clinical study with RUC-4, a novel subcutaneous platelet GPIIb/IIIa ...
The first study to examine the effects of whole-chocolate consumption on ex vivo platelet function has shown that dark chocolate acutely reduces collagen-stimulated platelet aggregation and reduces ...
Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...
When cancer cells and platelets mix, the risk of metastasis and cancer-related deep vein thrombosis (DVT) and pulmonary embolism (PE) increases, but a small, proof-of-concept study suggests that the ...
SAN FRANCISCO (MarketWatch) -- Inspire Pharmaceuticals Inc. said late Monday that it has terminated its Phase II clinical trial of INS50589 Antiplatelet, based on the unanimous recommendation of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results